Li et al. [33] demonstrated that empagliflozin (SGLT2i) attenuated DCM in type 2 diabetic cardiomyopathy in mice via inhibition of oxidative stress generated by NADPH oxidases. This evidence concerns the gene FMO5 and familial dilated cardiomyopathy.